CSL Ltd 2025 AR2
The report highlights CSL's solid performance for the fiscal year ended June 30, 2025, with annual revenue reaching US$15.6 billion and NPATA attributable to equity holders increasing by 11% to US$3.2 billion. The company achieved significant milestones, including the approval of its first internally developed monoclonal antibody, ANDEMBRY, in multiple global markets. CSL also advanced its sustainability strategy, securing SBTi approval for its near-term emissions reduction targets and achieving a 29% reduction in Scope 2 emissions. Additionally, the company expanded its partnership with the World Federation of Haemophilia to donate life-saving products to low- and middle-income countries.
Company: CSL Ltd
Sector: Health Care
Country: Australia
Year: 2025
Type: AR2
Pages: 148
CSL Ltd
Annual Report
The report highlights CSL's solid performance for the fiscal year ended June 30, 2025, with annual revenue reaching US$15.6 billion and NPATA attributable to equity holders increasing by 11% to US$3.2 billion. The company achieved significant milestones, including the approval of its first internally developed monoclonal antibody, ANDEMBRY, in multiple global markets. CSL also advanced its sustainability strategy, securing SBTi approval for its near-term emissions reduction targets and achieving a 29% reduction in Scope 2 emissions. Additionally, the company expanded its partnership with the World Federation of Haemophilia to donate life-saving products to low- and middle-income countries.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jul 1, 2024 - Jun 30, 2025
Fiscal Year
2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees